Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics filed a Form 144 notice reporting a proposed sale of 2,170 shares of Common Stock via a broker-assisted cashless exercise on 06/10/2026. The filing lists multiple recent dispositions by the reporting person between 03/09/2026 and 05/18/2026, including sales of 14,058 shares on 03/13/2026 for $369,225.07 and repeated smaller transactions. This notice documents affiliated share sales and an associated cashless exercise; timing and settlement mechanics are described as a broker-assisted cashless exercise.
Mineralys Therapeutics, Inc. entered into an underwriting agreement for a primary offering of 5,660,378 shares of common stock at $26.50 per share. Underwriters will purchase the shares at $25.3075 per share, and net proceeds to Mineralys are expected to be about $142.5 million after fees and expenses.
The offering is expected to close on or about June 4, 2026, subject to customary conditions, and is being conducted under an effective shelf registration statement and prospectus supplement. In its press release, Mineralys stated it intends to use the net proceeds to help fund a $200.0 million upfront payment to repurchase a royalty obligation under its license agreement with Tanabe Pharma Corporation, alongside a previously announced $500 million committed debt facility from funds managed by Pharmakon Advisors.
Mineralys Therapeutics is offering 5,660,378 shares of common stock. The prospectus supplement states an offering price of $26.50 per share and lists gross proceeds of $150,000,017 with underwriting discounts of $6,750,001, producing proceeds before expenses to the company of $143,250,016.
The company says it expects to receive approximately $142.5 million in net proceeds and intends to use those funds to finance a portion of a $200.0 million upfront payment to repurchase a royalty obligation under its license agreement with Tanabe Pharma Corporation. The supplement also discloses shares outstanding of 82,454,950 as of March 31, 2026, and projects 88,115,328 shares outstanding immediately after this offering.
Mineralys Therapeutics amended its license with Tanabe Pharma to eliminate future royalties on lorundrostat and reshape its payment obligations. The amendment grants Mineralys an exclusive, worldwide, royalty-free, sublicensable, perpetual license and removes diligence requirements for development and commercialization.
Mineralys will pay Tanabe a one-time $200.0 million cash payment and potential commercial milestone payments of up to $255.0 million, plus up to $10.0 million for a second indication. The company also entered a senior secured term loan facility of up to $500.0 million, with a $100.0 million Tranche A drawn at closing and additional tranches contingent on FDA approval of the lorundrostat NDA and specified net sales milestones.
Mineralys Therapeutics, Inc. held its 2026 annual stockholder meeting on May 21, 2026, where two proposals were voted on. Stockholders elected three Class III directors to three-year terms ending at the 2029 annual meeting and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals received the requisite affirmative vote of the company’s common stockholders.
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported a small, pre-planned stock transaction. He exercised stock options covering 417 shares of common stock at $15.44 per share and sold 417 common shares at $27.55 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 63,443 shares of common stock and 4,167 stock options, indicating this activity affected only a small portion of his overall position.
Mineralys Therapeutics submitted a Form 144 reporting a proposed sale of 417 shares of common stock on 05/18/2026 tied to an exercise of employee stock options. The filing lists the sale method as a broker‑assisted cashless exercise and shows multiple recent dispositions by David Rodman during Feb–May 2026.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a series of equity transactions in May. Over May 11–13, 2026, he sold a total of 22,575 shares of Mineralys common stock in open-market trades at weighted-average prices around the high-$20s per share.
On the same dates, he exercised stock options for 16,226 shares at strike prices ranging from $1.08 to $16.00 per share, converting option awards into common stock. After these transactions, he directly held 63,443 shares of common stock. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Mineralys Therapeutics, Inc. reported affiliated sales of common stock via Form 144, showing multiple dispositions through broker-assisted and cash transactions. The excerpt lists individual sales by David Rodman between 02/09/2026 and 05/12/2026, and shows an exercise-related transfer on 05/13/2026.
Mineralys Therapeutics submitted a Form 144 reporting a proposed sale of 6,348 shares of common stock on 05/12/2026, tied to a broker-assisted cashless exercise of employee stock options. The filing lists a sequence of prior dispositions by David Rodman across February–May 2026, shown as individual sales (examples include 14,058 and 6,348 share lots).